Medical Condition News

RSS

KSB, SuperNova sign agreement to develop and commercialize Neopterin

SuperNova Diagnostics, a privately-held global diagnostics company for human and non-human health applications, announced today that it has signed an agreement with Shenzhen Kang Sheng Bao Bio-Technology, a biotechnology diagnostics company specializing in research, manufacture and distribution of in-vitro diagnostic kits and research reagents in China and affiliated markets for the research, development, manufacture and commercialisation of diagnostic products and services for the measurement of Neopterin, its metabolites and derivatives utilising the SuperNova technology platform of AmpCrystal.

31 Mar 2011

Eating disorders - hitting early and hard

Children as young as seven have been admitted to hospitals for eating disorders. A peak support group has reported a doubling of calls about children under the age of 12 in the past decade. Being hit so early with these disorders also means malnutrition leading to retarded growth, osteoporosis, infertility and changes in brain structure say experts.

30 Mar 2011

New clinical practice guidelines developed for juvenile idiopathic arthritis

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community.

30 Mar 2011

Gilead and Yale enter multi-year cancer research collaboration

Gilead Sciences, Inc. and Yale School of Medicine today announced the formation of a multi-year research collaboration focused on the discovery of novel cancer therapies. The research effort will initially span four years with an option to renew for up to ten years.

30 Mar 2011

MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.

30 Mar 2011

AA Pharma launches Lithium Carbonate SR 300mg for Bipolar Disorder in Canada

AA Pharma Inc., a leading distributor of pharmaceuticals in Canada, is pleased to announce the launch of LITHMAX, a sustained release formulation containing 300mg of lithium carbonate. LITHMAX is indicated in the treatment of manic episodes of Bipolar Disorder, as well as the maintenance treatment for individuals with a diagnosis of Bipolar Disorder.

30 Mar 2011

Singing reduces blood pressure prior to total knee replacement surgery

Doctors report that singing reduced the blood pressure of a 76-year-old woman who had experienced severe preoperative hypertension prior to total knee replacement surgery for osteoarthritis (OA). While the patient was unresponsive to aggressive pharmacologic interventions, the woman's blood pressure dropped dramatically when she sang several religious songs.

30 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

BioSante completes patient enrollment in LibiGel Phase III trial against HSDD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the second of two pivotal Phase III LibiGel safety and efficacy trials has been completed. Enrollment in the first LibiGel efficacy trial was completed in February.

30 Mar 2011

XTRAC laser therapy can offer relief to patients with severe psoriasis

PhotoMedex, Inc. announced today the implications of the preliminary findings of a current clinical trial being performed by John Y.M. Koo, M.D., professor and vice chairman, department of dermatology, University of California, San Francisco. Dr. Koo's experimental treatment protocol could change the lives of millions of people suffering from moderate to severe psoriasis.

30 Mar 2011

Traditional Chinese herbal medicine is an effective skin whitening cream

Scientists today reported discovery of the active ingredients in an herb used in traditional Chinese medicine for skin whitening, changing skin color to a lighter shade.

30 Mar 2011

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.

30 Mar 2011

University of Leicester unveils plans for new CRC at Glenfield Hospital

The University of Leicester has unveiled plans for a £12.6m Cardiovascular Research Centre that will double the amount of space available for world-class heart research.

30 Mar 2011

IntraPace reports first commercial use of abiliti system in obese patients

IntraPace, Inc., announced today that the first commercial patients in Europe have successfully received the abiliti system as a treatment for obesity. The patients were treated at the Clinica La Luz in Madrid, Spain, and Stadtkrankenhaus Schwabach, Germany.

30 Mar 2011

FDA grants orphan drug status to America Stem Cell's ASC-101

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation.

30 Mar 2011

New stereo-EEG method can detect epileptic foci during surgeries

The neurosurgery department of HUCH has started to utilize stereo-EEG method for localizing the epileptic focus in severe epilepsy for epilepsy surgery purposes. The department is also getting ready to introduce the so-called deep brain stimulation therapy in the treatment of epilepsy.

30 Mar 2011

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced today new results from three studies that demonstrate the positive effects of the EndoBarrier Gastrointestinal Liner on type 2 diabetes, weight loss and other metabolic factors.

30 Mar 2011